Searchable abstracts of presentations at key conferences in endocrinology

ea0073js4.1 | ESE/SBEM, FASEN and SMNE Joint Session: Pituitary conditions and COVID-19 | ECE2021

Acromegaly and Covid-19

Bronstein Marcello D.

Acromegaly is a chronic disease caused almost invariably by a pituitary GH-secreting adenoma leading to overproduction of insulin-like growth factor I (IGF-I). The long-term hypersecretion leads to many comorbidities, as diabetes mellitus, arterial hypertension, and cardiovascular and/or pulmonary disease (including sleep apnea), which are related to an increased mortality rate. In fact, uncontrolled acromegaly is associated with a three times mortality rate as compared with n...

ea0063p731 | Pituitary and Neuroendocrinology 2 | ECE2019

Therapeutic decisions in acromegaly according to disease control in patients with acromegaly with or without prior treatment: data from baseline analysis of the SAGIT® validation study

Giustina Andrea , Bronstein Marcello , Chanson Philippe , Petersenn Stephan , Casanueva Felipe , Sert Caroline , Houchard Aude , Melmed Shlomo

Background: The SAGIT® instrument, designed to assist clinicians in staging and managing acromegaly, is undergoing validation. A descriptive analysis of SAGIT Validation study baseline data revealed discrepancies between investigator-evaluated disease-control status, disease activity, hormonal control, and treatment decisions in acromegaly.Objective: To describe the baseline characteristics of patients in the SAGIT® valida...

ea0032p906 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Treatment with pasireotide LAR normalizes prolactin levels in patients with acromegaly and hyperprolactinemia: randomized, double-blind, 12-month, phase III study

Colao Annamaria , Freda Pamela , Gu Feng , Resendiz Karina Hermosillo , Ruffin Matthieu , Chen YinMiao , Bronstein Marcello

Introduction: Around 20–30% of patients with acromegaly have hyperprolactinemia, which is associated with infertility and gonadal/sexual dysfunction. Current therapy involves somatostatin analogues for GH/IGF1 excess and a dopamine agonist to decrease prolactin levels. The objectives of this analysis were to assess treatment with pasireotide LAR or octreotide LAR alone in patients with acromegaly and hyperprolactinemia.Methods: Patients with acromeg...

ea0049ep1039 | Pituitary - Clinical | ECE2017

Monthly pasireotide provides clinical benefit over 12 months in patients with Cushing’s disease

Pivonello Rosario , Bronstein Marcello , Schopohl Jochen , Delibasi Tuncay , Barkan Ariel , Suzaki Nori , Tauchmanova Libuse , Gupta Pritam , Petersenn Stefan , Lacroix Andre

Introduction: A monthly, long-acting formulation of pasireotide normalized or reduced mean urinary free cortisol (mUFC) in most patients with Cushing’s disease (CD) in a multicentre, double-blind, Phase III study. The effects of long-acting pasireotide on signs and symptoms of CD are reported here.Methods: Patients with persistent/recurrent (n=123) or de novo (non-surgical candidates; n=27) CD and mUFC≥1.5–5xULN...

ea0090p682 | Pituitary and Neuroendocrinology | ECE2023

A rollover study for patients who continued to receive benefit from pasireotide at completion of an earlier trial (B2412): An 8-year interim analysis

Gadelha Monica , Bronstein Marcello , Grineva Elena , Kapoor Nitin , De Block Christophe , Miguel Escalante Pulido Jesus , Rollin Guilherme , Baggenstoss Rejane , Piacentini Andrea , Pedroncelli Alberto , Gallardo Wilson

Introduction: A robust clinical programme of 14 trials demonstrated pasireotide as an effective treatment for patients with rare endocrine disorders, including acromegaly and Cushing’s disease (CD). Patients with acromegaly or CD have significant morbidity, reduced quality of life and, if inadequately treated, higher mortality risk than the general population. This 8-year interim analysis evaluated long-term safety of pasireotide treatment in patients with acromegaly, CD ...

ea0037ep800 | Pituitary: clinical | ECE2015

Metformin-based oral antidiabetic therapy proved effective in hyperglycaemia associated with pasireotide in patients with acromegaly

Colao Anna Maria , Gu Feng , Gadelha Monica R , Lely Aart J van der , Fleseriu Maria , Passos Vanessa , Ravichandran Shoba , Chen Yin Miao , Bronstein Marcello D

Introduction: High affinity binding of pasireotide for both sst2 and sst5 leads to its enhanced efficacy in treatment of acromegaly but results in decreased secretion of insulin, incretins (GLP-1 and GIP) and, to a lesser extent, glucagon. Metformin may be a good option in patients with acromegaly experiencing hyperglycaemia with pasireotide as it improves GLP-1 secretion. We analysed data from a 12-month, Phase III, randomised study in medically naï...

ea0035p912 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Efficacy and safety of lanreotide autogel (LAN-ATG) 120 mg at extended dosing intervals (EDIs) in acromegalic patients biochemically controlled with octreotide LAR (OCT-LAR) 10 or 20 mg: The LEAD study

van der Lelij Art-Jan , Pronin Vyatcheslav , Balcere Inga , Lee Moon-Kyu , Rozhinskaya Liudmila , Bronstein Marcello , Gadelha Monica , Maisonobe Pascal , Sert Caroline

Introduction: EDIs with LAN-ATG therapy may help improve the burden associated with long-term acromegaly management. The LEAD study evaluated the efficacy and safety of this approach by switching from OCT-LAR conventional dosing to LAN-ATG EDI.Methods: LEAD was a multinational, multicentre, open-label, non-comparative study. Acromegalic patients with normal IGF1 after OCT-LAR 10 or 20 mg injections every 4 weeks for ≧6 months were switched to LAN-...

ea0032p845 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Pasireotide LAR and octreotide LAR maintain inhibition of GH and IGF1 in patients with acromegaly: 12-month extension phase of a randomized, double-blind, multicenter, phase III study

Sheppard Michael , Bronstein Marcello , Freda Pamela , Serri Omar , De Marinis Laura , Naves Luciana , Rozhinskaya Liudmila , Hermosillo Resendiz Karina , Ruffin Matthieu , Asubonteng Kobby , Colao Annamaria

Introduction: Pasireotide LAR was significantly superior to octreotide LAR at providing biochemical control in a 12-month trial in 358 medically naïve patients with acromegaly. Patients with clinical benefit or GH <2.5 μg/l and IGF1≤ULN could continue therapy in the extension study.Methods: Patients entering the extension (pasireotide LAR, n=74; octreotide LAR, n=46) were followed up to month 26 (core plus extension)...

ea0037ep810 | Pituitary: clinical | ECE2015

Pasireotide long-acting release maintains biochemical control in patients with acromegaly: results from the extension of randomised, Phase III, PAOLA study

Colao Anna Maria , Bronstein Marcello D , Brue Thierry , Coculescu Mihail , Marinis Laura De , Fleseriu Maria , Guitelman Mirtha A , Pronin Vyacheslav , Raverot Gerald , Shimon Ilan , Fleck Juergen , Kandra Albert , Pedroncelli Alberto M , Gadelha Monica R

Introduction: The PAOLA study in patients with inadequately-controlled acromegaly (n=198) demonstrated superior efficacy of pasireotide long-acting release (LAR; 40 mg/60 mg) in biochemical control (GH <2.5 μg/l and normalized IGF-1) vs continued treatment with octreotide LAR 30 mg/lanreotide Autogel 120 mg (15.4% and 20.0% vs 0%). Here we report preliminary data from the extension phase of PAOLA at wk28.Methods: Pasireotide-LAR (40 mg/...

ea0035p907 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Pasireotide LAR demonstrates superior efficacy versus octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: results from a phase III, multicentre, randomized study (PAOLA)

Gadelha Monica , Bronstein Marcello , Brue Thierry , Coculescu Mihail , Fleseriu Maria , Guitelman Mirtha , Pronin Vyacheslav , Raverot Gerald , Shimon Ilan , Lievre Kayo Kodama , Fleck Juergen , Aout Mounir , Pedroncelli Alberto , Colao Annamaria

Background: Some patients with acromegaly do not achieve biochemical control despite receiving maximum-approved doses of currently available somatostatin analogues. This 24-week, randomized study assessed the multireceptor-targeted somatostatin analogue pasireotide LAR vs octreotide LAR/lanreotide Autogel in patients with inadequately controlled acromegaly.Methods: Eligible patients: ≥18 years with mean GH levels ≥2.5 μg/l and IGF1 level...